Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

The High-Tech Cures for Rising Health-Care Costs

By Alex Planes - Updated Apr 7, 2017 at 5:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In the long run, progress does bring prices down.

A third of the world's population contracted the influenza virus between 1918 and 1920, and 50 million people died. Since warnings of a potential bird-flu pandemic began circling at the end of 2003, an estimated 332 people have died worldwide, all in developing countries. The first open-heart surgery was performed in 1952; today, more than half a million heart surgeries are performed each year in the United States alone. Medical science has arguably progressed further in the past century than it had in all prior human history, and the pace of progress appears to be accelerating. But there's no progress without cost.

Recent years have witnessed an explosion in health-care costs, causing particular consternation in the United States as our polarized political climate sharpens the debate over whether health care should be a right or a privilege. Despite all medicine's advancements -- or perhaps because of them -- we spend almost 4 times as much per person on health care as we did in 1970. If trends continue, the average cost of annual health-insurance premiums will be higher than most families' household incomes in the next 20 years.

As my colleague Morgan Housel pointed out in rebutting that ridiculous claim, trends tend not to continue in a straight line forever. Things change. The question will be what drives that change. Morgan identified compelling economic reasons why the current trajectory is unsustainable. I'll take a different angle, looking closer at the technology behind modern medicine and seeing how progress on the bleeding edge could arrest and reverse a decades-long bubble in health-care spending.

Agents of change
Although health care continues to be transformed by technological advancements, costs have not come down as they have in nearly every other arena where technology's been applied. The human body is, let's face it, a lot more complicated (and a lot more valuable) than a process on a factory floor, and we still know far less about how it works than we could. That could soon change.

I've identified three key technological trends working to make health care more effective and more affordable. They are:

  • Automation: doing the work of doctors with algorithms.
  • Robotics: performing surgery with far greater precision than human hands.
  • Genetics: understanding the inner workings of each unique body.

Call it ARG. Yes, the future sounds kind of like a pirate.

Automation
Applying computing power to medical diagnostics is not new, but for a long time it was subject to the limitations of computation and algorithmic capabilities. An archaic medical-records system hasn't helped, nor did the fact that medicine, like computing, has seen the frontiers of its knowledge and functionality rapidly expand in recent years. I briefly highlighted a robotic nurse when discussing the effects of automation last year, but that's only one of many possible examples.

The Becton, Dickinson (NYSE: BDX) FocalPoint medical imaging system, profiled in Slate last year, has nearly doubled a human examiner's speed of operation while simultaneously improving the ability to find cell abnormalities. Other machines can detect abnormalities in images of the colon, chest, and arteries. IBM (NYSE: IBM) may soon leverage its Jeopardy!-winning Watson supercomputer as a diagnostic tool. More applications will undoubtedly be forthcoming. Speeding the diagnostic process while reducing labor requirements and improving accuracy can and should reduce costs over the long term.

There will be worries that machines will make mistakes, but humans make plenty of mistakes as well. Medical errors in hospitals have been cited as the cause of anywhere from 100,000 to a million unnecessary deaths per year. Even the most conservative estimate is far too high to accept. Medical-technology companies afraid of malpractice suits may be protected by the Supreme Court's 2008 Riegel v. Medtronic decision, which ruled that FDA-approved devices are protected from consumer lawsuits. Replacing doctors with devices might therefore save money on insurance premiums as well.

Robotics
The encroachment of robotics into our hospitals should be no surprise to longtime Fool readers, who've been well aware of Intuitive Surgical (Nasdaq: ISRG) and MAKO Surgical (Nasdaq: MAKO) for years. These companies are not only great investment opportunities; they're also transforming the process of surgery itself. There may come a day when most surgeries, like the diagnostics I mentioned, are performed by robots controlled by highly sophisticated software, without the need for any direct human intervention. This won't happen any time soon, but in the long run, people will be as accepting of machine surgeons as they once were of bloodletting -- and machines are undeniably far more effective.

Genetics
This is the area that offers the greatest transformative potential in years to come. Despite all science's efforts, we still know precious little about how our genomes make us tick. That's in large part due to the oppressively high cost of genome testing, which is finally poised to break through the $1,000-per-test barrier later this year. That's beyond the reach of most people, but my projections see testing costs approaching the price of a fast-food hamburger before the end of the decade. When you consider that a full-genome sequencing cost millions a mere decade ago, that's incredible progress.

Illumina (Nasdaq: ILMN) and Life Technologies are on the vanguard of this growing field, but their technology alone won't create the transformation we need. There's a vast chasm between information and knowledge. For example, Alzheimer's is well understood from a genetic standpoint but poorly served by current treatments. Complex diseases require vast amounts of information to be processed into meaningful analyses and viable prescriptions, and a broad base of cheaply sequenced genomes would be the necessary starting point to bridge that chasm. There may be fewer than 50,000 sequenced human genomes today. Imagine the wealth of information unlocked by the sequence of millions.

Imagine medicine tailored not to general symptoms but specific genetic markers. It would greatly cut down on both prescription-drug abuse and accidental drug-related deaths, which now outnumber car-related fatalities in the United States. Of course, it should also greatly improve the quality of care, as patients can be treated as individuals rather than symptoms. The combination of genetics and analytics may offer the greatest chance we have of breaking the cycle of rising medical costs -- provided the results are used for effective treatment instead of profit-seeking.

ARG, matey
I'm not here to suggest that things are about to turn around. It's taken decades to reach this point, and there may be decades ahead before the dream of affordable universal health care comes to pass. But technology will have its part to play, as it always has. We can cure diseases we couldn't identify a century ago, and we can fix many defects that would have felled our parents and grandparents.

Even so, there's still a long way to go before science can say it really understands the human body. The gulf between information and knowledge continues to shrink with each passing year, and with it the need for unnecessary procedures shrinks, the risk of death lowers, and (so the theory goes) the costs of restoring health should fall. It's taken billions of years to create human beings, so a few more years to understand them should be worth the cost in the long run.

What do you think will happen to medicine once technology begins to really understand how we tick? Let me know with a comment.

Medicine might not see the next big technology transformation, but this industry will. Find out more about one company poised to reap windfalls in the next trillion-dollar revolution. All the info you need is right here in The Motley Fool's free report. Claim your copy now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

International Business Machines Corporation Stock Quote
International Business Machines Corporation
IBM
$121.58 (1.39%) $1.67
MAKO Surgical Corp. Stock Quote
MAKO Surgical Corp.
MAKO.DL
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$340.49 (5.16%) $16.72
Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
BDX
$250.36 (1.71%) $4.22
Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$369.43 (5.06%) $17.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.